Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Experts To Industry: Start Implementing Social Media Guidelines Now

This article was originally published in The Gray Sheet

Executive Summary

While FDA’s oversight and expectations for device makers using social media is still hazy, two experts advise companies to put together policies outlining their interpretation of new agency guidances on the topic and how they plan to comply.

You may also be interested in...



Critics Call FDA Third-Party Social Media Guidance ‘Overbroad’

Some stakeholders are concerned the agency’s draft guidance is overreaching and could have a chilling effect. AdvaMed recommends FDA consider splitting the guidance into product-specific documents to reference regulations that may apply to industries differently.

FDA Twitter Guidance Lacks Flexibility, And May Be Unconstitutional, Critics Say

Stakeholders say the agency’s communication requirements for space-limited online platforms are too restricting and violate the First Amendment. Many of them are calling on the agency to withdraw the guidance and try again. The device industry has a comparatively toned down response so far, but wants more flexibility.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel